Drug Trial Radar · NCT05639894
Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
865
Actual
Start
Nov 17, 2022
Primary completion
May 2, 2025
Study completion May 2, 2025
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Brief Summary of Stage 1: The purpose of Stage 1 (Phase I/IIa) was to assess the safety and immunogenicity of a single intramuscular (IM) injection of 3 dose-levels of an Respiratory Syncytial Virus (RSV) vaccine candidate formulated with 2 different lipid nanoparticles (LNPs) in healthy adult participants aged between 18 to 50 years, and 60 years and older. The primary objectives of this stage were to assess the safety and immunogenicity profiles across the dose-level groups (low, medium, and high doses) with 2 LNPs. This stage evaluated the safety and immunogenicity of a booster vaccination administered 12 months after the primary vaccination in a subset of the study population. Brief Summary of Stage 2: The study also incorporated a Stage 2 (Phase IIa, dose-ranging design) that included adults aged 60 years and older to assess the safety and immunogenicity of different doses of RSV vaccine encapsulated in one of the LNPs. In the Phase IIa dose-ranging stage, eligible participants were randomly assigned in a 1:1:1 ratio to receive a single IM administration of RSV vaccine candidate doses, or placebo. Multiple safety analyses were performed, minimally at D07 and D28.
Conditions
- Respiratory Syncytial Virus Immunization
Interventions
RSV vaccine candidateBiological
Pharmaceutical Form: Liquid frozen solution in a vial Route of Administration: Intramuscular injection
PlaceboOther
Pharmaceutical Form: Liquid Route of Administration: Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)Time frame: Up to 30 minutes post-primary vaccination on Day 1
- Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Solicited Injection Site Reactions and Systemic ReactionsTime frame: From Day 1 (first dose of primary vaccination) up to Day 8 (7 days post-primary vaccination on Day 1)
- Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Unsolicited Adverse EventsTime frame: From Day 1 (first dose of primary vaccination) up to Day 29 (28 days post-primary vaccination on Day 1)
- Stage 1 (Sentinel and Main Cohort): Number of Participants With Medically Attended Adverse Events (MAAEs)Time frame: From Day 1 (first dose of primary vaccination) up to Day 29 (28 days post-primary vaccination on Day 1)
- Stage 2: Number of Participants With Medically Attended Adverse EventsTime frame: From Day 1 (first dose of primary vaccination) to Day 180
- Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)Time frame: From Day 1 (first dose of primary vaccination) to Day 365 (Stage 1 Sentinel and Main Cohorts); From Day 1 (first dose of primary vaccination) to Day 180 (Stage 2)
- Stage 1 (Sentinel and Main Cohort) and Stage 2: Number of Participants With Shifts From Baseline to Out-of-Range Biological Test ResultsTime frame: From baseline (Day -14 to Day -1) up to Day 8 (7 days post-primary vaccination on Day 1)
- Stage 1 (Sentinel and Main Cohort): Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against Respiratory Syncytial Virus ATime frame: Day 1 (pre-primary vaccination) and Day 29 (28 days post-primary vaccination on Day 1)
- Stage 2: Geometric Mean Titers of Neutralizing Antibodies Against Respiratory Syncytial Virus A and Respiratory Syncytial Virus BTime frame: Day 1 (pre-primary vaccination) and Day 29 (28 days post-primary vaccination on Day 1)
Locations
33 sites in 3 countries. Site status is shown where the registry gives one.
Optimal Research Alabama Site Number : 8400032
Huntsville, Alabama
Aventiv Research Mesa Site Number : 8400020
Mesa, Arizona
CVS Health - Peoria Site Number : 8400042
Peoria, Arizona
CVS Health - Phoenix Site Number : 8400041
Phoenix, Arizona
Velocity Clinical Research - San Diego - ERN - PPDS Site Number : 8400010
La Mesa, California
Peninsula Research Associates Site Number : 8400013
Rolling Hills Estates, California
CVS Health - Thousand Oaks Site Number : 8400043
Thousand Oaks, California
Cenexel Research Centers of America Site Number : 8400024
Hollywood, Florida
Suncoast Research Associates, LLC Site Number : 8400003
Miami, Florida
Centricity Research - Georgia Site Number : 8400009
Rincon, Georgia
AES Peoria Site Number : 8400030
Peoria, Illinois
DM Clinical Research - Chicago Site Number : 8400027
River Forest, Illinois
Be Well Clinical Studies Site Number : 8400036
Lincoln, Nebraska
Velocity Clinical Research Site Number : 8400019
Cincinnati, Ohio
Velocity Clinical Research Site Number : 8400017
Cleveland, Ohio
Aventiv Research Columbus Site Number : 8400007
Columbus, Ohio
Lynn Institute of Norman Site Number : 8400023
Norman, Oklahoma
Velocity Clinical Research, Medford Site Number : 8400014
Medford, Oregon
Velocity Clinical Research - Providence Site Number : 8400006
East Greenwich, Rhode Island
Coastal Carolina Research Center Site Number : 8400015
North Charleston, South Carolina
DM Clinical Research - CyFair Site Number : 8400025
Houston, Texas
Be Well Clinical Studies -Round Rock Site Number : 8400038
Round Rock, Texas
IMA Clinical Research-San Antonio Site Number : 8400039
San Antonio, Texas
Martin Diagnostic Clinic Site Number : 8400026
Tomball, Texas
Velocity Clinical Research Site Number : 8400018
West Jordan, Utah
Investigational Site Number : 0360001
Southport, Australia
Investigational Site Number : 0360003
Botany, New South Wales, Australia
Investigational Site Number : 0360002
Camberwell, Victoria, Australia
Investigational Site Number : 6300004
Carolina, Puerto Rico
Investigational Site Number : 6300003
Guayama, Puerto Rico
Investigational Site Number : 6300005
Guaynabo, Puerto Rico
Investigational Site Number : 6300001
San Juan, Puerto Rico
Investigational Site Number : 6300002
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.